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Summary
Illicit drug use is associated with many risks of harm to the user and to their family and friends. The harms 
associated with methylamphetamine, especially its crystal (ice) form are particularly concerning, and 
can result in significantly harmful long-term psychological and physical effects. Changes in the use of 
methylamphetamine have been one area of increasing concern among health professionals and the  
Australian community.
Terminology for methylamphetamine—commonly referred to as methamphetamine or ‘meth’—varies 
across data sources. Not all data sources collect data on methylamphetamine specifically; some use the 
broader classes of drugs, amphetamines, amphetamine-type stimulants, or ‘meth/amphetamines’, in which 
methylamphetamine belongs. Box 2 provides a description of each of the terms used throughout this report.
   Production and supply of amphetamine-type stimulants has been increasing.
In recent years, arrest, seizure and detection data indicate that production and supply of amphetamine-type 
stimulants (ATS) is rapidly increasing, both in Australia and internationally. Over the four years since 2009–10, 
detections (the identification of illicit drugs at the Australian border) increased by 86% between 2011–12 and 
2012–13, and a further 18% in 2013–14, and the total weight of these detections in 2013–14 was 27 times as 
high as it was in 2009–10. The total number of arrests for ATS increased—accounting for 15% of all arrests in 
2009–10 and 23% in 2013–14.
   Methylamphetamine is consistently reported as very accessible.
As well as consistent prices, methylamphetamine purity has remained consistently high since 2008, particularly 
for crystal, and all forms of methylamphetamine have been consistently reported as ‘easy‘ or ‘very easy’ to obtain 
since 2007.
   The form of methylamphetamine used has changed from powder to crystal in recent years.
While the proportion of the population who used meth/amphetamines in the last 12 months declined 
between 2004 and 2013 (from 3.2% to 2.1%), more recently there has been substantial change in the 
form of methylamphetamine used—from powder to crystal (ice). More of those who recently used 
methylamphetamine in 2013 reported crystal as the main form used (50% of recent users) compared with 
powder (29% of recent users).
   Between 2010 and 2013, there has been an increase in new users of ‘meth/amphetamine’,  
  especially crystal.
In 2013, a larger proportion of recent users had first used ‘meth/amphetamines’ within the last 3 years  
(that is, they were ‘new users’ of the drug since the last data collection period)—34%, compared with 27% in  
both 2007 and 2010. This cohort of new users is opting mainly for crystal rather than the powder form of  
‘meth/amphetamines’.
   Since 2004, there has been a shift in the pattern of recent ‘meth/amphetamine’ use by    
  socioeconomic status, remoteness area and Indigenous status.
In 2013, recent users of  ‘meth/amphetamine’ were more commonly aged 20–29 and most likely to be male. In 
2004, people living in the two most advantaged socioeconomic status (SES) quintiles were the more likely to be 
recent users of meth/amphetamine. However, by 2010 they were the least likely to be users. Since 2007, people 
living in Remote and very remote areas and Aboriginal and Torres Strait Islander people (hereafter referred to as 
‘Indigenous Australians’) were more likely to be recent ‘meth/amphetamine’ users. 
   Since 2009–10 the number of episodes for clients injecting and smoking amphetamines  
  has increased.
Over the 5 years to 2013–14, the number of episodes for clients both injecting and smoking (clients who 
reported ‘smoking’ or ‘inhaling’) amphetamines increased, while use via other methods remained relatively 
stable. Clients who smoke amphetamines are most likely to have never injected drugs, indicating that these 
clients are a different type of user. While characteristically, injectors and smokers appear to be relatively similar, 
there are some noticeable differences—more young people smoke than inject and slightly more females and 
Indigenous Australians inject than smoke.
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1 Introduction
Illicit drug use is associated with many risks of harm to the user and to their family and friends. People who 
use illicit drugs place themself at risk of health problems, exposure to violence, family breakdown, crime and 
housing difficulties (NRHA 2012, Stafford & Burns 2015). In 2013, around 2.9 million people in Australia reported 
they had used illicit drugs in the previous 12 months (AIHW 2014). Both nationally and internationally, the 
proportion of people using illicit drugs has remained relatively stable over the last 10 years—15% of adults in 
Australia in 2013, and globally around 5% of the adult population in 2010 (AIHW 2014, UNODC 2012). However, 
usage patterns continue to change. Changes in the use of methylamphetamine have been one area of 
increasing concern among health professionals and the Australian community.
The harms associated with methylamphetamine, especially its crystal (ice) form, are particularly concerning. 
Crystal is highly addictive and causes disruption to an individual’s brain function. Crystal use can also result in 
harmful long-term psychological and physical effects, such as paranoia, substance dependence, memory loss, 
liver damage and cardiovascular diseases (Darke et al. 2007).
In Australia, the National Drug Strategy (NDS) has provided the overarching framework for addressing licit and illicit 
drug use since 1985. The broad aims of the NDS are to prevent and reduce the uptake and misuse of drugs, the 
production and supply of illicit drugs and the negative social, economic and health consequences of drug use. The 
NDS addresses the production and use of methylamphetamine in a number of ways (see Box 1 for further details).
Box 1: Policy context
National Drug Strategy
Two iterations of the NDS cover most of the time period considered in this report; the National Drug 
Strategy 2004–2009 and the National Drug Strategy 2010–2015. These strategies are underpinned by the 
principle of harm minimisation encompassing three components (pillars): demand reduction, supply 
reduction and harm reduction. Together, they aim to prevent/reduce: the uptake and misuse of drugs; the 
production and supply of illicit drugs; and the negative social, economic and health consequences of drug 
use. The National Drug Strategy 2010–2015 identified that there is a continuing high domestic production of 
amphetamine-type stimulant (ATS) drugs, an increasing number of ATS-related arrests and that problematic 
behaviour and organised crime associated with ATS use are issues of concern.
There are a number of sub-strategies developed under the NDS to address illicit drugs, ATS drugs or 
precursor chemicals specifically. These may contribute to the reduction in demand, supply and harm 
patterns related to amphetamines observed over time.
National Amphetamine-Type Stimulant Strategy 2008–2011 (ATS strategy)
The ATS strategy was released under the National Drug Strategy 2004–2009 in response to increased 
production, use, purity and harms of ATS in Australia, observed over the prior 10–15 years (MCDS 2008). 
There is no current ATS strategy.
National Strategy to Prevent the Diversion of Precursor Chemicals into Illicit Drug Manufacture 
(National Precursor Strategy)
The National Precursor Strategy was funded from 2003–2008 under the National Drug Strategy 2004–2009 to 
reduce the supply of precursor chemicals used to produce illicit drugs in clandestine laboratories. In 2007,  
the Australian Government provided the National Precursor Strategy with recurrent annual funding.
National initiatives
A number of national initiatives are funded and/or implemented under the NDS framework. These 
initiatives are aimed at building the capacity of health, education and law enforcement sectors and include 
interventions to prevent drug-related harm (Miller et al. 2009). Over the period of time from 2003, this has 
included phase two to five of the National Drugs Campaign and a grants program specifically for ATS.
Further information on national and complementary sub-strategies, national initiatives and state and 
territory policies are available online.
For more information on policies in Australia, see the supplementary document to this report, Policy related 
to methylamphetamine in Australia between 2003–04 and 2013–14.
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Due to the significant negative consequences of methylamphetamine use (crystal specifically) on individuals 
and their families, the Australian Government has launched a National Ice Taskforce to develop the National 
Ice Action Strategy to address the use of ice and its impacts. The taskforce delivered an interim report to the 
Council of Australian Governments (COAG) on 23 July 2015 and the strategy will be delivered to COAG by the 
end of 2015 <http://www.dpmc.gov.au/taskforces/national-ice-taskforce>. 
Alcohol and other drug treatment services (AODTS) play an important role in efforts to reduce the recent trends 
in methylamphetamine use (AIHW 2011). 
This report presents data on the use, availability and market activity of methylamphetamine over the period 
2003–04 to 2013–14 and compares these with trends in drug treatment. The analyses presented in this report 
provide insights for policy makers and practitioners to tailor intervention strategies and services to reduce 
the harms associated with methylamphetamine. They also indicate possible areas for further, more targeted 
research. See Box 2 for an explanation of terminology used in this report. 
Data sources
There are several data sources that have been used in this report; see Table 1 for descriptions of each data 
source. Collectively these data present the most representative national picture of methylamphetamine. 
The National Drug Strategy Household Survey (NDSHS) is the leading national survey of licit and illicit drug 
use in Australia and the main source for data on meth/amphetamine use at a national level. Data sources 
like the Illicit Drug Reporting System (IDRS) and the Ecstasy and Related Drugs Reporting System (EDRS) 
capture the characteristics of drug use among specific sub-populations; injecting drug users in the IDRS and 
psychostimulant users in the EDRS. The Australian Secondary Schools Alcohol and other Drug (ASSAD) Survey 
is a national survey of licit and illicit drug use among secondary school students. The Alcohol and Other Drug 
Treatment Services National Minimum Dataset (AODTS NMDS) is a comprehensive administrative dataset of 
people receiving services for their drug and alcohol-related issues. 
Data used in this report are not exhaustive, nor is each data source without limitations. For example, some 
data sources did not collect annual data over the entire period (2003–04 to 2013–14). Differences exist across 
the data sources on terminology (see Box 2), analysis variables and population samples make the synthesis of 
findings from these multiple sources difficult. For more information on the limitations of each data source,  
refer to the ‘Data gaps and limitations’ section.
Table 1: Description of data sources presented in this report
Data Source Description
National Drug Strategy Household 
Survey (NDSHS)
Survey that collects information on alcohol and tobacco consumption, and 
illicit drug use among the general population in Australia. It also surveys 
people’s attitudes and perceptions relating to tobacco, alcohol and other 
drug use
Alcohol and Other Drug Treatment 
Services National Minimum Data Set 
(AODTS NMDS)
Administrative data on the treatment provided by publicly-funded AODTS  
in Australia
Illicit Drug Reporting System (IDRS) National illicit drug monitoring system to identify emerging trends in illicit 
drug use, in particular heroin, methylamphetamine, cocaine and cannabis
Ecstasy and Related Drugs Reporting 
System (EDRS)
National monitoring system for ecstasy and related drugs used to identify 
emerging trends in ecstasy and related drugs markets
Drug Use Monitoring in Australia 
(DUMA)
Program which examines the relationship between drugs and crime, and 
monitors local drug markets and drug use patterns by detainees across time
Illicit Drug Data Report (IDDR) The IDDR uses the National Illicit Drug Reporting Format system to process 
seizure, arrest and purity data
Australian Secondary School 
students Alcohol and Drug (ASSAD) 
Survey
Survey of secondary school students on their use of tobacco, alcohol,  
over-the-counter and illicit substances
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Box 2: Terminology
The literature on methylamphetamine and amphetamine contains a variety of terms; in some instances 
these terms cover similar, but not the same range of drugs. This can be confusing when interpreting 
results across different data sources. In this report, each section reflects the terminology used by the 
corresponding data source. Below is a description of each term used in these data sources and the types of 
drugs they encompass:
•	 Amphetamine-type	stimulants—covers a large range of drugs, which includes amphetamines, 
methylamphetamines and phenethylamines (a class of drug that includes MDMA or ‘ecstasy’). This 
term is used in the Illicit Drug Data Report (IDDR).
•		 Amphetamine(s)—refers to the broad category of amphetamines in the Australian Standard 
Classification of Drugs of Concern (ASCDC) (ABS 2011). This includes amphetamine, 
methylamphetamine, dexamphetamine and amphetamine analogues, and this term is used in the 
AODTS NMDS.
•	 Meth/amphetamine includes methylamphetamine and amphetamine, this is the term used in the 
National Drug Strategy Household Survey (NDSHS).
•	 Methylamphetamine also comes in different forms, including powder/pills (speed), crystal 
methylamphetamine (crystal meth or ice), a sticky paste (base), and a liquid form. These are referred to 
here as powder, base, crystal and liquid.
See ‘Glossary’ for definitions of the different types of drugs and drug forms.
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2 Availability and the illicit drug market
The Australian heroin drought in the early 2000s generated much research into the causes and consequences 
of its reduced availability. Research from this, and a subsequent United Kingdom heroin drought, found that 
reduced supply and availability had an effect on purity, price, and patterns of use (for examples, see Degenhardt 
et al. 2006; Harris et al. 2015).
These aspects of the illicit drug market (supply, purity, price and use) are often used in analyses of drug 
availability; however, these factors are not independent and their relationships can be complex  
(Degenhardt et al. 2006; Bush et al. 2004; Caulkins 2005). For example, key seizures and arrests at the time of 
the Australian heroin drought are often cited as key to its reduced availability. Others have argued that a shift 
in the preference of suppliers to producing other drugs, such as methylamphetamine had more influence on 
availability (Bush et al. 2004).
More recently, trends in all factors related to the market of methylamphetamine indicate it is very accessible. 
And, despite cannabis dominating the illicit drug market (for example, see Figure 1) these trends have made 
ATS, and methylamphetamine specifically, the primary drug of concern of the Australian Crime Commission 
(ACC) in 2014 (ACC 2015). 
The analyses presented here cover the following components of the illicit drug market: 
•	 production and supply—as indicated through arrest, seizure and detection data
•	 price and purity—thought to be affected by the supply of a drug
•	 availability—as recorded by users, and affected by all of the above.
For further information on the data sources used in this section, see Table 1.
Production and supply
Reducing drug supply is one of the key pillars of the National Drug Strategy (NDS) (MCDS 2011). Disrupting the 
production and supply of illicit drugs generally falls to state, national and international policing and customs 
agencies. Two key reports quantify the efforts of such agencies, the Illicit Drug Data Report (IDDR), produced by 
the ACC, and the World Drug Report, produced by the United Nations Office on Drug Crime (UNODC). These 
reports generally provide information relating to ATS, which covers amphetamine, methylamphetamine and 
phenethylamine (which includes MDMA, or ‘ecstasy’). Where this is referred to in this report as ATS (excluding 
MDMA), it covers amphetamine and methylamphetamine.
As mentioned above, analyses of drug market changes are complex and problematic, especially of drug 
production and supply. As Willis and others (2006) point out, available indicators—such as arrest, seizure and 
detection data—can be more indicative of law enforcement activity than changes in drug markets themselves.
In recent years, arrest, seizure and detection data indicate that production and supply of ATS is rapidly 
increasing, both in Australia and internationally—particularly in Asia (ACC 2015; UNODC 2012). 
   In the last three years there have been record numbers of arrests, numbers and weight of  
  seizures and border detections of ATS. 
In Australia, the number of ATS (excluding MDMA) detections has increased dramatically since 2008–09  
(ACC 2015). Between 2011–12 and 2012–13, detections increased by 86%, and by a further 18% in 2013–14.  
The total weight of these detections increased by 516% from 2011–12 to 2012–13, and by a further 15% in 
2013–14 (ACC 2015). The number of national seizures followed similar trends, with a 27% increase from 2012–13 
to 2013–14, and although the national weight of seizures decreased by 37% over the same period, it was still 
the third highest on record. Over the last four years, the total number of arrests for ATS increased—accounting 
for 15% of illicit drug arrests in 2010–11 and 23% in 2013–14 (Figure 1). Consumers accounted for three-quarters 
(76%) of all ATS arrests in 2013–14 (see Glossary for definition of  ‘consumer’).
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The number of clandestine laboratories detected in Australia more than doubled from 2003–04 to 2013–14—
from 358 to 744. Of these, the majority were identified as producing ATS (excluding MDMA) (ACC 2015). This 
mirrors international trends, with the UNODC reporting that ATS are the most common illicit drugs produced in 
clandestine laboratories globally (UNODC 2012).
Price and purity
Studies examining the heroin droughts of both Australia and the United Kingdom found that a significant 
decrease in the availability of heroin led to large increases in its price, and big decreases in its purity 
(Degenhardt et al. 2006; Harris et al. 2015). In a study by Chalmers and others (2010), meth/amphetamine users 
reported they would reduce their use in response to a hypothetical increase in price, although, as the authors 
point out, intention does not always lead to behaviour.
In 2014, around three-quarters of people using the powder, base and crystal forms of methylamphetamine 
reported stable prices (NDARC 2015b). In fact, injecting users have reported a relatively stable price of all three 
forms since 2009. Powder has been the most stable form, remaining at $50 per point (0.1 gram) and $150  
per half gram since 2009. Per gram and half-gram, users consistently report crystal as the most expensive  
form of methylamphetamine—between $400 and $600 per gram and between $200 and $300 per half-gram.
While these users are reporting relatively stable prices over time, using a purity-adjusted price of both powder 
and crystal based on Victorian data, Scott and others (2015) argue that the increasing purity of crystal means the 
price of both powder and crystal are effectively on par and the price of both has decreased over time. 
   Consistently high levels of purity have been reported for all forms of meth/amphetamine since  
  2008, particularly for crystal.
As well as consistent prices, methylamphetamine purity has remained consistently high since 2008. Depending 
on the form, its purity appears to be either increasing or remaining relatively stable over time. Both injecting 
drug users and psychostimulant users are reporting increasing levels of powder purity, with a 16 and 12 percentage 
point change, respectively, in users reporting high levels of purity from 2008 to 2014. The purity of base and 
crystal has been reported as more stable over the same period, although fewer psychostimulant users are 
reporting high levels of purity for crystal in recent years (62% of users in 2012 and 49% in 2014) (NDARC 2015b; 
NDARC 2015a).
Note: ‘nec’ refers to not elsewhere classified.
Source: ACC 2015.
Figure 1: Number of arrests, by type of drug, 2003–04 to 2013–14
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Availability
   All forms of methylamphetamine are consistently reported as very accessible since 2007.
Given the picture presented so far, it is not surprising that users are reporting methylamphetamine as very easy  
to obtain, with injecting users, psychostimulant users and police detainees all reporting high availability  
(NDARC 2015b, NDARC 2015a, Coghlan & Goldsmid 2015). For example, in 2014, over 80% of injecting users who 
commented on availability reported powder, base and crystal as either easy or very easy to obtain (NDARC 2015b). 
Since 2009, an increasing proportion of injecting users have reported crystal as either easy or very easy to 
obtain—from 64% of users in 2009 to 91% in 2014; a 27 percentage point increase in 5 years (NDARC 2015b). Since 
2013, crystal has overtaken powder as the most obtainable form reported by injecting users (Figure 2). As these 
results were reported by injecting users only they may not reflect the experiences of all methylamphetamine users.
While the picture presented in this section is of broad-level analyses only, it indicates a concerning story about 
the market for methylamphetamine. User reports of easily accessible methylamphetamine are supported by 
evidence of high volumes being produced both nationally and internationally, at high levels of purity and 
relatively stable prices. Continued analysis of these trends will be essential to assess the impact of new strategies 
on limiting the availability for this drug.
Source: NDARC 2015b.
Figure 2: Methylamphetamine reported as easy or very easy to obtain, by injecting drug  
users, 2004 to 2014 (%)
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3 Use
Use of meth/amphetamine refers to both illicit use of meth/amphetamine (use of illegal meth/amphetamine), 
and also to illicit use of legal meth/amphetamines (for example, Ritalin) for non-medical purposes. 
Meth/amphetamine, as used in this section, covers both methylamphetamine and amphetamine. High doses 
of meth/amphetamine can have multiple negative consequences, including dependence, induced psychosis 
and violent behaviour. Methylamphetamine comes in many forms including powder/pills (speed), crystal 
methylamphetamine (crystal meth or ice) and a sticky paste (base). The ‘high’ experienced from the crystal and 
base form is much more intense, and generally accompanied by more powerful responses (DoH 2015). 
Box 3 presents additional information related to the interpretation of this section.
Box 3: Technical information
Data in this section is drawn from the National Drug Strategy Household Survey (NDSHS). Recent use of 
meth/amphetamines is defined as use in the previous 12 months. Patterns of use over this period will vary 
among recent users, from those who have only tried meth/amphetamine once or twice, to frequent users 
of the drug (weekly or more often). 
The term meth/amphetamine used in this section refers to both amphetamine and methylamphetamine.
The data presented for crystal use only represents those people who reported that they used crystal as 
their main form in the previous 12 months; the number is likely to be higher as it does not represent all 
crystal users.
Some estimates have relative standard errors of 25% to 50% and should be used with caution. Estimates 
with relative standard errors greater than 50% have been suppressed. Please refer to NDSHS supplementary 
tables for further information.
Note, while data presented in this section cover the Australian population they may not be representative 
of particular population groups. See ‘Data gaps and limitations’ for a description of the coverage of each 
data source used in this section. 
Who uses meth/amphetamines?
In 2013, around 1.3 million (7.0%) Australians had used meth/amphetamine in their lifetime, and about 400,000 
(2.1%) had used them recently (Figure 3; Table S1). Lifetime and recent use has declined over time, and between 
2004 and 2013, there has been a reduction in the number of people using meth/amphetamine recently (by 
around 100,000 people) (Table S1). Compared with other illicit drugs, the number of lifetime and recent users 
of meth/amphetamine in Australia are lower than cannabis, ecstasy and cocaine, with substantially higher 
numbers of cannabis users than any other illicit substance (Figure 3). 
Source: Table S1.
Figure 3: Lifetime and recent use of drugs in Australia, 2004 to 2013
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Data from the 2011 ASSAD survey indicate that 2.9% of secondary school students aged 12–17 had used 
amphetamines in their lifetime, a significant decline from 5.3% in 2005 (White & Bariola 2013). Recent use of 
amphetamines among secondary school students is similar to the general population—2.2% of 12–17 year old 
students had used amphetamines in the past year. Among this group, the likelihood of use increases with age, 
with 1.1% of 12 year olds being recent users, increasing to 4.5% for 17 year olds (White & Bariola 2013).
Poly drug use is common among recent meth/amphetamine users. In 2013, recent users also reported consuming 
alcohol (86%), tobacco (68%), cannabis (50%) and ecstasy (30%) at the same time as meth/amphetamine  
(Table S9). Overall, those mainly using crystal were more likely to use tobacco, cannabis and cocaine at the  
same time than those mainly using powder. Crystal users were 1.6 times as likely to misuse cannabis than  
those mainly using powder. 
In 2013, recent users of meth/amphetamine were more commonly aged 20–29 and most likely to be male.
In 2013, males were more likely than females to have used meth/amphetamine in their lifetime (8.6% and 5.3% 
respectively) and recently (2.7% and 1.5% respectively), and this has remained the case over time (Figure 4). 
In 2013, the largest age group of recent meth/amphetamine users was 20–29, for both males and females.  
Since 2004, those aged 20–29 have been more likely to use meth/amphetamine recently, although the 
proportion using has declined steadily over this time period (Table S4). 
The next most common age group of users, after 20–29 year olds, was 14–19 year olds (2.0%); however,  
recent use has declined substantially over time for this group (from 4.4% in 2004) (Table S4).
   In 2013, for recent users of meth/amphetamine higher rates were reported among those  
  unemployed/looking for work, living in Remote or Very remote areas, never married or single  
  (with or without dependent children), or homosexual/bisexual*.
In 2013, recent meth/amphetamine users were 4.5 times more likely to report being homosexual/bisexual  
than heterosexual (Table S6) and 2.5 times more likely to report being unemployed/looking for work than 
employed (Table S5).
From 2004 to 2013, these groups were consistently more likely to use meth/amphetamine than their counterparts.
Given that recent meth/amphetamine use is more common among people aged 14–39 (mean age of use  
in 2013 was 30 years), higher rates observed for people who have never married or are single are consistent  
with the younger age profile of these groups (Table S6). 
* The characteristics of meth/amphetamine users described here are not mutually exclusive and often overlap with other characteristics.  
For example people with low SES are often unemployed, and/or do not have educational qualifications. In addition, people within  
disadvantaged groups may experience different levels of disadvantage and belong to one or multiple groups.
Source: Table S4.
Figure 4: Recent use of meth/amphetamine, people in Australia aged 14 or older, 2004 to  
2013 (%)
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   In 2013, higher rates of recent use of meth/amphetamine were reported by those experiencing  
 high or very high levels of psychological distress or having a mental illness.
Compared with meth/amphetamine users who had not used in the previous 12 months, recent users of  
meth/amphetamine were 2.7 times more likely to experience high or very high levels of psychological distress 
and 2.1 times as likely to report having a mental illness in 2013 (Table S9). From 2004 to 2013, recent users were 
consistently more likely to report higher levels of psychological distress and mental illness than those who had 
not used meth/amphetamine recently. By themselves, these findings do not establish a causal link between 
mental illness and drug use—the mental illness may have preceded the drug use or vice versa (AIHW 2010).
   Since 2004, there has been a shift in the pattern of recent meth/amphetamine use by SES,  
 remoteness area and Indigenous status.
In 2004, people living in the two most advantaged SES quintiles had the highest rates of recent use of  
meth/amphetamine. However, by 2010 and 2013 they were the least likely to be users. From 2004 to 2013,  
while recent use among those living in the two most advantaged SES areas declined, the proportion of recent 
users among the 3 lower quintiles generally increased (Table S5).
Since 2007, Remote and very remote areas were the regions with the highest rates of recent meth/amphetamine 
use (with the rate of use increasing substantially between 2004 and 2013, from 0.9% to 4.4%) (Table S8). Prior to 
2007, people living in Major cities were more likely to be recent users (2.4% compared with 0.9% for Remote and 
very remote areas in 2004).  
Between 2004 and 2013 the proportion of Indigenous Australians recently using meth/amphetamine went 
from 2.0% in 2004 to 3.1% in 2013 with fluctuations during this period (Table S7). Since 2007, Indigenous people 
were more likely to be recent users of meth/amphetamine than non-Indigenous people—estimates for recent 
use of meth/amphetamines among Indigenous Australians in 2010 and 2013 should be interpreted with 
caution due to high relative standard error rates, see Box 3. Prior to 2007, non-Indigenous Australians were  
more likely to be recent users, however the proportion using decreased substantially between 2004 and 2013 
(from 5.5% to 2.0%).
What form of methylamphetamine are people using?
Methylamphetamine comes in many forms including powder/pills (speed), crystal methylamphetamine (crystal 
meth or ice) and a sticky paste (base). The ‘high’ experienced from crystal and base is much more intense, 
generally with more powerful responses including comedown, chronic, physical and mental problems and the 
potential for dependence (addiction) (DoH 2015). 
   While the proportion of the population who used meth/amphetamine in the last 12 months  
 declined between 2004 and 2013 (from 3.2% to 2.1%), more recently there has been substantial  
 change in the form of methylamphetamine used—from powder to crystal (ice).
The NDSHS collects both the main form of methylamphetamine used and all forms used for both lifetime and 
recent use. From 2004 up until 2010, recent methylamphetamine users were more likely to have used powder 
rather than crystal. However, between 2010 and 2013, the proportion of recent users who ever used powder 
significantly decreased (from 83% to 65%) (Figure 5). Over the same period, recent users reporting powder 
as the main form of methylamphetamine used significantly decreased from 51% in 2010 to 29% in 2013 (or a 
reduction of around 80,000 recent users) while the use of crystal as the main form more than doubled (from 
22% or around 80,000 people to 50% or around 200,000 people), making crystal the most common form of 
methylamphetamine ever used and mainly used by recent users in 2013 (Figure 5). 
In 2013, while 50% of recent users reported crystal as the main form used, 72% had used it at some time in their 
lifetime—a statistically significant increase from 51% of recent users in 2010 having ever used crystal indicating 
a significant take up of crystal during that period (Figure 5).
In 2013, powder was most likely to be snorted (65%), while crystal was most likely to be smoked (78%). Between 
2010 and 2013 there was a significant increase in the proportion of recent meth/amphetamine users smoking 
the drug (from 19% to 41%) (Table S11). The shift over time in method of use for all methylamphetamine 
forms—from mostly being swallowed or snorted to being smoked—reflects the shift in main form used from 
powder to crystal.
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Data from the IDRS also indicates a shift in the main form of methylamphetamine used by people who inject 
drugs (PWID). Between 2003 and 2011, higher proportions of PWID using methylamphetamine in the previous 
six months reported using powder more than any other form (from 55% to 44%) (NDARC 2015b). However from 
2011 onwards, more PWID reported using crystal than powder in the previous six months, and the gap between 
the two forms increased over that period (from 45% and 44% in 2011 to 61% reporting using crystal and 30% 
reporting using powder in 2014) (NDARC 2015b).
New users
   Between 2010 and 2013, there was an increase in new users of meth/amphetamine,  
  especially crystal.
In 2013, a larger proportion of recent users had first used meth/amphetamine within the last 3 years (that is, 
they were ‘new users’ of the drug since the last data collection period)—34%, compared with 27% in both 2007 
and 2010 (Figure 6). Among users who had first used meth/amphetamine more than 4 years ago—there was a 
decline from 73% in 2007 to 67% in 2013 (Table S12).
The shift from powder to crystal as the preferred form observed between 2010 and 2013 was not only fuelled 
by previous users switching main form, but also by new meth/amphetamine users opting for crystal. In 2013, 
43% of recent meth/amphetamine users reporting crystal as the main form used were new users, up from 26% 
in 2007 and 29% in 2010 (Table S12).
Similarly, the increase in new users of crystal is reflected in the increase in the number of recent meth/amphetamine 
users who had ever used crystal in their lifetime between 2010 and 2013, which had remained fairly constant 
prior to 2010.
Using crystal as the main form decreased as age increased—those aged 14–19 were more likely to report 
mainly using crystal (61%), followed by 20–29 year olds (52%). This was a substantial change from 2007,  
with the proportion of users across both age categories mainly using crystal more than doubling (from 23%)  
(Table S13). The younger profile of recent meth/amphetamine users mainly using crystal highlights that new 
users are predominantly younger—with an average age of 22 years for recent users’ first use. The younger profile 
of crystal users also appears to be reflected among people receiving treatment—with half (50%) of the treatment 
episodes for people who are smoking or inhaling amphetamines aged 20–29 (see ‘Treatment’ section).
Source: Table S10.
Figure 5: Number of Australians who mainly used crystal in the previous 12 months,  
2007 to 2013
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Frequent users
High doses and frequent use of methylamphetamine can cause amphetamine-induced psychosis (characterised 
by symptoms similar to paranoid schizophrenia), increased risk of suicide, violent behaviour, diminished effects 
over time (leading to users increasing their dose to achieve intoxication), and methylamphetamine dependence 
(Campbell 2001).
   Recent users of meth/amphetamine are using the drug more frequently—especially when  
 crystal is the main form used.
Between 2004 and 2010, the proportion of recent meth/amphetamine users using the drug at least once a week 
or more fluctuated between 13% and 9.3% (Table S15). However, between 2010 and 2013, the proportion using 
meth/amphetamine at least weekly significantly increased to 16%—the highest it has been since 2004 (Figure 7). 
Note: This figure represents the minimum number of crystal users, it does not necessarily represent all crystal users in the population.  
Information is not available prior to 2007 for main form used, frequency of use and years since first use of crystal specifically.
Source: Table S14.
Figure 6: Frequency of crystal use among recent meth/amphetamine users in Australia,  
2004 to 2013
Note: Information is not available prior to 2007 for main form used for crystal and powder.
Source: Table S15.
Figure 7: Australians who frequently used meth/amphetamine, and recent users of  
meth/amphetamine, by form used, 2004 to 2013
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In 2013, people who reported mainly using crystal used the drug more frequently than powder users—46% 
and 19% respectively, using at least once a month. Similar to recent users of any meth/amphetamine, between 
2007 and 2013, there was only a small difference in recent users whose main form was crystal who used weekly 
or more (23% and 25% respectively) (Table S15). However, a low of 12% in 2010 means that those using crystal 
at least once a week or more doubled by 2013. 
Data from the IDRS indicates that the trend in frequency of crystal use has also been observed among the PWID 
population and it has continued past 2013. From 2010 to 2013, the median number of days use in the last six 
months for crystal use surpassed the number of days for powder use—10 days for powder and 7 days for crystal 
in 2010, compared with 10 days for powder and 12 for crystal in 2013 (NDARC 2015b). In 2014, the frequency 
of crystal use continued to increase, with the median number of days for crystal use increasing from 12 days in 
2013 to 20 days in 2014. Conversely, the frequency of powder use decreased from 10 to 6 days (Figure 8).
Unsuccessful efforts to cut down or control use of methylamphetamine, even with the desire to do so, is 
an indicator of methylamphetamine dependence (Campbell 2001). In 2013, recent users who mainly used 
crystal were more likely to report being unable to stop or cut down their use, even though they wanted to 
(15% compared with 12% of all meth/amphetamine users). They were also more likely to report the reason for 
continued crystal use as addiction/dependency or wanting to improve mood/stop feeling unhappy, compared 
with all recent meth/amphetamine users.
Note: The median number of days for any form includes the speed powder, base, ice (crystal) and liquid forms.
Source: NDARC 2015b.
Figure 8: Injecting drug users who used meth/amphetamines in the previous  
6 months, median days use, by form used, 2013 and 2014
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4 Treatment
Many types of treatment are available in Australia through alcohol and other drug (AOD) treatment services 
to assist people with problematic drug use. Most aim to reduce the harm of drug use, for example counselling 
and diversion programs, while others use a structured drug-free setting with abstinence-oriented interventions. 
This section presents information on treatment episodes delivered by publicly-funded treatment services for 
AOD use from the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) (see 
‘Data gaps and limitations’). Information is presented on amphetamines, which includes methylamphetamine. 
Information on the different forms of amphetamines used is not captured in the AODTS NMDS. However, it does 
capture the client’s usual method of administering their drug of concern which is a strong indicator of the form used.
In 2013–14, AOD treatment services provided a total of 180,713 closed treatment episodes, an increase of 32% 
since 2003–04 (136,869 episodes). While there are many different drugs people receive treatment for, the most 
common principal drugs of concern (the primary drug leading someone to seek treatment)—which are alcohol, 
cannabis, heroin and amphetamines—have accounted for the large majority of services over time (Figure 9). 
Who receives treatment for amphetamine use?
Amphetamines were the third most common principal drug of concern (17% of all episodes), behind alcohol 
(40%), cannabis (24%) in 2013–14. Heroin was the next main principal drug of concern (7.0% of episodes). Since 
2003–04, the proportion of episodes where amphetamines were the principal drug of concern has increased 
(from 11% to 17%), despite falling to a low of 7.2% in 2009–10 (Table S18).
In almost two-thirds (63%) of episodes with a principal drug of concern of amphetamines, the client reported 
additional drugs of concern. These were most commonly cannabis (31%), alcohol (22%) and nicotine (20%). 
   In 2013–14, treatment episodes for clients using amphetamines were most likely to be males  
 and more commonly aged 20–29; the same profile seen for meth/amphetamine users.
In 2013–14, in two-thirds of treatment episodes with a principal drug of amphetamines, the clients were male 
(68%). This has remained consistent since 2003–04 (Figure 10). While clients were more likely to be aged 20–29 
(40% of episodes in 2013–14), there has been a decrease in this age group since 2003–04 when it accounted for 
Source: Table S18.
Figure 9: Closed treatment episodes provided for own drug use, by selected principal drug of 
concern, 2003–04 to 2013–14
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48% of episodes. Concurrently, there has been an increase in clients aged 40–49 over this time period—from 
7.0% of episodes in 2003–04 to 15% in 2013–14. This pattern is consistent with the profile of all episodes for 
clients receiving treatment for AOD issues. Most clients with a principal drug of concern of amphetamines  
were aged 20–39 (75%) in 2013–14, followed by those aged 40–49 (15%) and 10–19 (8.4%) (Figure 10).
In 2013–14, around 1 in 10 (11%) clients receiving treatment reported being Indigenous Australians. The 
proportion of treatment episodes where amphetamines were the principal drug of concern was higher for  
non-Indigenous clients—17% compared with 14% for Indigenous Australians (Table S22).
   Counselling was the most common service for amphetamine-using clients and they spend a  
  median duration in treatment of just over 4 weeks.
In 2013–14, the most common main treatment type (the primary activity used to treat the client’s AOD 
problem) for episodes where amphetamines was the principal drug of concern was counselling (45%), 
followed by assessment only (19%) and withdrawal management (11%) (Table S29). This distribution is similar 
to treatment episodes for other commonly reported drugs, especially for counselling, which is consistently the 
highest reported treatment type. Since 2003–04 the proportion of episodes where counselling was the main 
treatment type increased (from 38% to 45%). For Indigenous clients counselling was also the main treatment 
type received (46% of episodes in 2013–14) and this has also increased since 2003–04 (from 36% to 46% of 
episodes) (Table S29).
Treatment was most likely to take place in a non-residential treatment facility (70%) and last a median duration 
of just over 4 weeks (29 days)—longer when compared to all treatment episodes in 2013–14 (23 days)  
(Table S31). However, episode duration varied by the main treatment type—episodes for counselling had a 
median duration of 8 weeks (56 days), while episodes with withdrawal management ended within 1 week 
(7 days) and information and education only lasted a median duration of 1 day. The median days spent in 
treatment was very similar for Indigenous clients, with a median duration of 28 days overall, and a median of  
53 days spent in counselling (Table S31).
For most treatment episodes where amphetamines were the principal drug of concern the referral source was 
self/family (43%), followed by diversion and health services (both 21%). Three-fifths (62%) of episodes ended 
with an expected cessation. Expected cessation was most common where diversion was the referral source 
(78%). One-quarter (25%) of episodes ended with an unexpected cessation (Table S31).
Sources: Tables S20 and S21.
Figure 10: Closed treatment episodes provided for own drug use with a principal drug of 
concern of amphetamines, by sex and age, 2003–04 to 2013–14
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   People are more likely to receive treatment for amphetamines in Major cities, but from 2003–04  
  to 2012–13 the number of treatment episodes in Regional and remote areas of Australia  
  increased slightly.
From 2003–04 to 2012–13 there was an increase in the geographic spread of treatment episodes across 
Statistical Local Areas (SLA) in Australia (Figure 11). Overall, this represented a change of around two percentage 
points; with an increase in the number of episodes across Regional and remote areas (24% in 2003–04 to 26% in 
2012–13) and a decrease across Major cities (76% to 74%) (Table S32).
 
 
Notes
1. Geographic location is based on the location of the treatment agency where the person receives treatment.
2. Both maps use 2011 SLA boundaries, therefore data for 2003–04 have been aggregated to 2011 SLA boundaries. Due to changes in  
 boundaries over time, data presented in the map for 2003–04 here may not map directly to the SLA data provided in 2003–04.
3.  Data for 2013–14 is not presented here as it cannot be compared to 2003–04, due to the change in geographic classification from  
 Statistical Local Area (SLA) to Statistical Area 2 (SA2) in 2013–14.
Source: AODTS NMDS.
Figure 11: Closed treatment episodes with amphetamines as the principal drug of concern by 
statistical local area, 2003–04 and 2012–13
 2003–04
 2012–13
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Method of use for clients receiving treatment
While information on the different forms of methylamphetamine is not captured in the AODTS NMDS, it does 
capture the client’s usual method of administering their principal drug of concern. For amphetamines this can 
provide an indication of the form a client used. For example, those smoking (clients who report either smoking or 
inhaling amphetamines) will be using the crystal form and those ingesting or snorting are most likely to be using 
the powder form. For clients injecting amphetamines it is less clear as each of the base, crystal, powder, or liquid 
forms, can be injected. But, according to the most recent data from the IDRS, of injecting users who were injecting 
methamphetamines, crystal was the form most often used in the month preceding interview (NDARC 2015b).
Note, where a client’s usual method of use is referred to as smoking, this includes where a client reported 
smoking or inhaling as their usual method of use.
   Since 2009–10 the number of episodes for clients injecting and smoking amphetamines  
  has increased.
In 2013–14, injecting was the most common usual method of use (44% of episodes), closely followed by 
smoking (41%) (Figure 12). Over the 5 years to 2013–14, the number of episodes for clients who were injecting 
and smoking amphetamines both increased, while use by other methods did not change. Therefore, the 
increase in the number of amphetamine episodes is accounted for by these two methods of use. Across the  
11 year period from 2003–04 however, clients were half as likely to be injecting in 2013–14, whereas over the 
same period clients were 12 times as likely to be smoking (Figure 12). 
The increase in smoking also resulted in a substantial decrease in the difference between the number 
of episodes where injecting is the usual method of use and where smoking is the usual method (Figure 12). 
Proportionally, injectors comprised over two-thirds (79%) and smokers 3.5% of all amphetamines episodes in 
2003–04, whereas, in 2013–14 this split was closer to even, with 44% of injectors and 41% of smokers (Figure 12).
These trends in method of use for treatment episodes parallel those seen in the population of recent  
meth/amphetamine users, where between 2010 and 2013 there was a substantial change in the main form  
of meth/amphetamine used—from powder to crystal (see ‘Use’ section).
   Most clients who are smoking amphetamines have never injected drugs.
Interestingly, most clients who smoke amphetamines report that they have never injected drugs in a large 
proportion of episodes (68% of episodes in 2013–14), and this is also relatively consistent over time (Figure 13). 
This pattern suggests that those who smoke amphetamines are a different type of user to those who inject 
amphetamines.  
Source: Table S24.
Figure 12: Closed treatment episodes provided for own drug use with a principal drug of 
concern of amphetamines, by method of use, 2003–04 to 2013–14
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   Clients who inject drugs may be using amphetamines and heroin interchangeably.
From 2003–04 to 2013–14, the consistent pattern found for amphetamines is also seen for injecting users. 
When comparing this pattern against other drugs of concern, a distinct relationship with heroin emerges, 
with complementary trends over the same time period (Figure 14). Perhaps most interestingly, where there 
were consistently more episodes for heroin use prior to 2013–14, in 2013–14 there were more episodes where 
amphetamine was the principal drug of concern now accounting for 47% of episodes, while heroin accounted 
for 37%. For Indigenous clients, this pattern is similar but less pronounced. What is clear, however, is that since 
2009–10, treatment episodes for amphetamines have increased substantially (from 5.5% to 14% of episodes), 
whereas heroin has decreased over the same time (from 6.0% to 4.8%) (Figure 14).
Sources: Tables S26 and S28.
Figure 13: Closed treatment episodes for clients who inject or smoke amphetamines, by time 
since last injected, 2003–04 to 2013–14
Source: Table S27.
Figure 14: Closed treatment episodes for clients injecting, by principal drug of concern, 2003–
04 to 2013–14
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   Younger users more commonly smoke than inject; slightly more females and Indigenous  
 Australians inject than smoke.
While characteristically, injectors and smokers appear to be relatively similar, there are some differences. The 
most noticeable difference is for Indigenous clients who are injecting, with the number of episodes nearly 
doubling from 2003–04 to 2013–14—from 8.9% to 16% (Table 2).
Slightly more females inject than smoke, which has been consistent over time—32% to 35% of episodes  
from 2003–04 to 2013–14 for injectors, compared with 28% to 30% for smokers (Table 2). There has also been 
a consistently greater proportion of Indigenous than non-Indigenous female clients injecting over the same 
period—ranging between 32%–43% of episodes for Indigenous female clients compared with 30%–34% of 
episodes for non-Indigenous female clients.
Clients who smoke are more commonly aged 20–29 (50%), whereas the largest proportion of clients who  
inject are aged 30–39 (41% of episodes)—although a large proportion of clients injecting are also aged 20–29 
(31% of episodes) (Table 2). While for Indigenous clients, those who smoke or inject are more commonly aged 
20–29 (51% and 39% of treatment episodes). However, as with all clients who inject, there is also a large proportion 
of injecting Indigenous clients who are aged between 30 and 39 (38% of treatment episodes) (Table 2). 
Table 2: Closed treatment episodes for clients who inject or smoke amphetamines, by selected 
characteristics, 2003–04 to 2013–14 (%)
03–04 04–05 05–06 06–07 07–08 08–09 09–10 10–11 11–12 12–13 13–14
Smokes
Males 73.4 70.3 71.7 72.6 72.2 72.8 76.4 73.2 74.2 72.5 69.9
Females 27.6 29.7 28.1 27.4 27.8 27.2 23.5 26.6 25.8 27.4 30.0
10–19 26.8 29.3 24.1 19.8 15.8 16.0 10.2 12.8 12.8 14.6 12.3
20–29 49.3 47.5 51.7 54.5 54.3 51.3 48.5 49.9 49.9 49.8 49.7
30–39 18.8 18.4 19.8 20.4 22.2 24.2 29.6 26.9 26.9 25.8 27.2
40–49 4.7 3.9 3.9 4.2 6.6 7.4 10.2 9.0 9.0 8.2 9.3
50+ 0.4 0.5 0.5 0.7 0.9 1.0 1.5 1.5 1.4 1.6 1.5
Indigenous 6.4 4.6 4.5 5.0 4.8 5.1 5.3 5.3 5.4 6.6 7.4
Non-Indigenous 87.2 92.1 92.0 91.8 91.6 89.9 88.8 89.8 90.3 80.1 83.0
Injects
Males 67.9 66.7 66.9 65.5 66.3 65.2 67.0 65.9 67.2 66.6 65.2
Females 32.1 33.2 33.0 34.5 33.7 34.8 32.9 34.1 32.7 33.4 34.8
10–19 8.9 8.9 7.9 6.4 5.4 5.2 4.6 4.7 4.4 4.7 4.7
20–29 48.8 46.2 43.8 43.3 41.7 39.2 37.2 34.6 34.0 33.3 31.0
30–39 33.9 35.7 37.7 39.0 40.1 40.7 40.4 42.0 42.1 41.0 41.1
40–49 7.2 7.3 9.0 9.8 11.4 13.3 15.8 15.8 17.1 18.4 19.9
50+ 0.5 0.9 1.2 1.3 1.2 1.5 1.9 2.4 2.4 2.5 3.3
Indigenous 8.9 10.9 10.5 10.4 10.7 11.9 12.4 13.2 12.9 15.0 16.4
Non-Indigenous 85.7 84.6 85.6 85.8 85.7 83.2 83.7 83.6 83.4 81.8 78.8
Source: AODTS NMDS.
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5 Trends in availability, use and treatment
Analysis of the trends in the drug market, use among the population and treatment received for 
methylamphetamine can provide useful insights into the full extent and impacts of methylamphetamine use.  
In turn, this can also provide researchers and policy makers with indicators of where to focus their efforts in 
future strategies and interventions to reduce the associated harms related to the use of methylamphetamine. 
   When comparing crystal users with clients in treatment for amphetamines, and other  
 meth/amphetamine data sources, several concurrent patterns emerge.
The prevalence in lifetime and recent use of any meth/amphetamine in Australia decreased between 2004 and 
2013 (from 9.1% to 7.0% for lifetime use and 3.2 % to 2.1% for recent use in the population). While the number 
of recent users of meth/amphetamine has also declined and stabilised in this period, the number of lifetime 
users has fluctuated—decreasing from 2004 to 2007, but increasing from 2007 onwards (from around  
1.1 million to 1.3 million people in 2013) (Figure 15).
However, during this same period, crystal use has increased. Among recent meth/amphetamine users, increases 
were seen in the number mainly and ever using crystal and in the number frequently using crystal (Figure 16). 
For example, there were around 105,000 more recent meth/amphetamine users who used crystal as their main 
form in 2013 compared with 2007. Note, this only represents those people who reported that they used crystal 
as their main form in the previous 12 months; the number is likely to be higher as it does not represent all 
crystal users.
Source: Table S1.
Figure 15: Lifetime use of meth/amphetamine and recent use of meth/amphetamine (used  
in the previous 12 months), 2004 to 2013
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   The number of all crystal users and treatment episodes for amphetamines decreased between  
 2007 and 2010, then from 2010 onwards the use, treatment and availability of crystal increased.
Analysis of data from several sources shows some major shifts in use, availability and treatment between 2004 
and 2013. 
Overall, between 2007 and 2010 there were decreases across use, availability and treatment. In 2007, crystal 
use among recent meth/amphetamine users and treatment for clients using amphetamines appeared to have 
reached a peak (220,000 recent users who had ever used crystal and 22,000 recent users whose main form was 
crystal using frequently; 17,000 treatment episodes). 
Following this, there was a distinct decrease to 2010 (189,000 who had ever used crystal and 10,000 recent users 
with a main form of crystal using frequently; 13,000 treatment episodes). 
The reported availability of crystal also follows these patterns—as reported by injecting users (Figure 17), 
psychostimulant users and police detainees (NDARC 2015b, NDARC 2015a, Coghlan & Goldsmid 2015).
From 2010, the decline was reversed and consistent increases across all data sources occurred up to the most 
recent data available in 2014. The number of recent users who were mainly using and frequently using crystal in 
2013 increased to 200,000 and 51,000, respectively, and the number of treatment episodes for amphetamines 
increased to 22,000. 
Note: Treatment data relates to episodes, a person may have multiple treatment episodes in a reporting year. Information on crystal specifically 
is not available prior to 2007 for main form used and frequency of use.
Sources: Tables S10 and S18.
Figure 16: Recent meth/amphetamine users who ever used, mainly used, and frequently  
used crystal in the previous 12 months, and closed episodes for clients receiving treatment 
for amphetamines, 2004 to 2013
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   Since 2010–11 the number of arrests, seizures and detections for amphetamine-type   
  stimulants has increased substantially.
The number of arrests, seizures and detections of ATS has increased since 2010–11 (Figure 17). Record-breaking 
numbers were recorded for all three areas in the last 3 years (see ‘Availability and the illicit drug market’ section).
While this analysis has highlighted some significant trends, it is not able to identify the reasons behind 
the trends. The increases seen in availability and use from 2010 to present are likely to be influenced by a 
productive methylamphetamine market in Australia and overseas (see ‘Availability and the illicit drug market’ 
section). Additionally, government programs aimed at increasing the capacity of treatment services in 2007–08 
and 2009 would have had an impact on the number of treatment episodes reported since these years (see 
‘Policy related to methylamphetamine in Australia between 2003–04 and 2013–14’). 
Similarly, the decline in availability and use from 2007 to 2010 would have been influenced by the concurrent 
decline in the number of seizures, detections and arrests over the same period. Plus, a substantial reduction 
in the weight of seizures and detections over the same period would also have had an impact on availability 
and use—in 2010 these were one-eighth and one-quarter the size of what was reported in 2007 (ACC 2015). 
However, a reduction in the reporting of these may not necessarily reflect a reduction of the availability of 
ATS (Willis et al. 2006). Similarly, media campaigns implemented in 2007 aimed at creating awareness of the 
negative consequences of powder and crystal may have had some influence in the decline in users and 
treatment in this period.
Note: Data for use, purity and availability are from the IDRS. Data on arrests and seizures are from the IDDR. Data for treatment are  
from the AODTS NMDS. Data are presented as percentages due to the different samples and counting units across each data source,  
Direct comparisons across each data source should be made with caution (see ‘Data gaps and limitations’). 
Sources: Table S18, NDARC 2015b, ACC 2015.
Figure 17: Trends in use, availability, purity, arrests and treatment of meth/amphetamine, 
2004 to 2013
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6 Implications for policy
From 2003 to 2014, several clear and related trends can be seen for the use, treatment, availability and ‘criminal’ 
activity relating to methylamphetamine. While only high-level analyses are presented here, they provide useful 
insight and direction for the focus of further, more detailed analyses that may guide work to reduce the use, 
supply and availability of methylamphetamine in Australia.
Further analysis of the factors that contributed to the decreases in use, treatment and availability from 
2007 to 2010 may assist policy makers in developing interventions and strategies to slow and reverse the 
subsequent increases seen from 2010 to present. Concurrent implementation of strategies, such as the National 
Amphetamine-Type Stimulant Strategy 2008–2011, and media campaigns released through the National 
Drug Campaign suggest they may have had an impact leading to this decrease. Indeed, studies of the media 
campaign in 2007 found that young people who recognised the commercials were more likely to have a 
negative view of methylamphetamine (SRC 2008).
Additionally, gaining an in-depth understanding of the habits and needs of users and people receiving 
treatment can help inform the development of effective education and treatment to reduce the use of 
this drug. For example, understanding the reasons for the increase in use of crystal over other forms of 
methylamphetamine, and treatment clients who are smoking amphetamines will be invaluable to preventing 
the uptake of the drug. Data development to enable and improve the capture of the different forms of 
methylamphetamine in the AODTS NMDS and NDSHS will also enhance the capacity to monitor these kinds 
of trends into the future. Further research into understanding whether clients who inject drugs are replacing 
amphetamine use for heroin will help to tailor treatment programs to assist these clients. 
Finally, evaluation of the impact that strategies implemented by the Australian Government’s National Ice 
Taskforce have on future trends in use and treatment of methylamphetamine will provide further evidence  
for what can work. 
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7 Data gaps and limitations
The data sources examined in this report differ in their purpose, population, scope, counting units and 
information captured (for example, the questions asked and terminology used). These differences mean that 
data are not directly comparable across the data sources, and that results from each data source may not 
necessarily be indicative of the whole population. The patterns presented across data sources in this report are 
intended to indicate where further research and enhancements to data could help improve the understanding 
of methylamphetamine in Australia.
It is also important to note that the data sources used here are not exhaustive of the information available on 
this subject. Additional data sources available at AIHW include:
•	 National Opioid Pharmacotherapy Statistics Annual Data collection 
•	 National Hospital Morbidity Database 
•	 Online Services Report Database 
•	 National Prisoner Health Data collection. 
Table 3 provides a description of the data sources used in this report.
Table 3: Detailed information of data sources, 2003 to 2014
Data Source Reference period Sample/Scope Counting Units
NDSHS Conducted every 
3 years since 
1985. Certain 
data for meth/
amphetamines  
are only available 
from 2007 
onwards
Sample survey of Australian residents aged either 12–14 years  
or over (depending on state or territory)
Sample size: around 24,000 in 2013
Residential households, excluding institutional settings, hostels, 
motels and homeless people. Foreign language interviews not 
conducted
Households are selected in a multistage, stratified area  
random sample
People (users)
AODTS 
NMDS
Every financial 
year from  
2003–04 onwards
AODTS that are publicly-funded—either by state and territory 
governments (the majority of AODTS), or by the Australian 
Government under the Non-Government Organisation 
Treatment Program (NGOTGP)
795 agencies in 2013–14
Includes clients aged over 10 years
Closed treatment 
episodes
IDRS Conducted 
annually since 
1997
Quantitative survey of people who inject drugs aged 16 years 
and over
898 clients in 2014
Semi-structured interview of experts
Collation of indicator data on drug-related issues
People (users and 
experts) Drug 
Indicators
EDRS Conducted 
annually since 
2003
Interviews of regular ecstasy and psychostimulant users  
aged 16 years and over
800 clients in 2014
Semi-structured survey of experts
Collation of indicator data on drug-related issues
People (users and 
experts) Drug 
Indicators
DUMA Quarterly Interviews and urine specimens of detainees held in custody  
in previous 48 hours. Nine sites across six jurisdictions
People (police 
detainees)
IDDR Every financial 
year from  
2002–03 onwards
Arrests, seizure and detection data are compiled from each state 
and territory policing agency, the Australian Federal Police (AFP)
Border detections are handed to the AFP from the Australian 
Customs and Border Protection Service (ACBPS)
People (arrests)
Drugs (seizures, 
detections), by 
number and weight
ASSAD Every three years 
from 1984 to 2011
Students in years 7 to 12 are randomly sampled across Australia. 
Sampling techniques are designed to be representative of 
government, Catholic and independent schools
Includes students aged 12 to 17 years
Sample size: around 25,000 in 2011
People (secondary 
school students)
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Further information on these data sources, including their scope and limitations, is outlined below.
AODTS NMDS
It is difficult to fully quantify the scope of AOD services in Australia. There are a variety of settings in which 
people receive treatment for AOD-related issues that are not in scope for this collection. These include agencies 
that: do not receive any public funding; primarily provide accommodation (for example sobering-up shelters); 
are based in correctional institutions; provide services primarily concerned with health promotion; are located 
in acute care/psychiatric hospitals and only provide treatment to admitted patients; or have the sole function 
of prescribing or providing dosing services for opioid pharmacotherapy (these data are captured in the AIHW’s 
National Opioid Pharmacotherapy Statistics Annual Data collection).
The AODTS NMDS does not cover all agencies providing substance-use services to Indigenous Australians. 
These agencies provide data to the Online Services Report collection. 
Data from the AODTS NMDS presented in this report are based on information about closed treatment 
episodes and are therefore not directly comparable to data presented on people, as a person may have multiple 
treatment episodes in a reference period.
Data available for amphetamines correspond to the ASCDC for the general ’amphetamines’ classification, in 
which, ‘methylamphetamine’ is a sub-classification. Since half (51%) of the responses to the sub-classifications 
of amphetamines in 2013–14 were for ‘amphetamines general’, data quality was not considered high enough 
to report on methylamphetamine specifically. This has improved significantly over time, though, with 
‘amphetamines general’ accounting for 83% in 2003–04. 
Data on the different forms of amphetamines, methylamphetamine specifically, are not separately available due 
to the nature of the classification structure used in this collection.
NDSHS
The NDSHS is the leading national survey of licit and illicit drug use in Australia and the main source for data on 
meth/amphetamine use at a national level. While data cover a significant range of people, they do not represent 
all of the Australian population. For example, people in institutional settings, hostels, motels and homeless 
people are not included. Foreign language interviews are not conducted. The information completed in the 
survey is self-reported.
Estimating the number of crystal (ice) users
It is not possible to calculate the exact number of crystal (ice) users as the series of questions in the survey 
are about meth/amphetamine use and the survey only asks the main form of meth/amphetamine used. It’s 
possible to estimate the minimum number of people using crystal (ice) but not a definitive number of users. 
The main form of meth/amphetamine used was only added to the questionnaire in 2007 therefore trend data 
for crystal (ice) users is only available from 2007 onwards.
Changes to meth/amphetamine questions in the NDSHS
The questionnaire is generally modelled on the previous versions of the survey to maintain maximum 
comparability. However, some refinements are made to ensure the questions remain relevant and useful.
Between 2004 and 2010, questions relating to meth/amphetamine use were refined to more accurately reflect 
substances used in Australia. More specifically in 2007 the term ‘meth’ was introduced and in 2010 clarification 
about non-medical use was added. Before 2004 the term ‘meth’ was not included.
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IDDR
The IDDR is the best source of arrest and seizure data in Australia. While there are some limitations (provided 
below), use of the National Illicit Drug Reporting Format (NIDRF) system to process arrest, seizure and purity 
data allows for more accurate analysis of the data and assists in the improvement and development of 
nationally standardised data holdings (ACC 2015).
Data presented on criminal activity in the IDDR are a synthesis of data received from several sources, including 
policing agencies from each state and territory, the Australian Federal Police and the Australian Customs and 
Border Protection Services. As such, there are certain limitations with this data. For example, differences in 
the recording and storing of information for some records, quality control resulting in missing information, 
differences in counting and data extraction methodology, differences in consumer and provider offences over 
time, differences in drug and offence coding, insufficient drug identification, and the inability to identify seizures 
resulting from  joint operations (for example, those involving AFP and a state or territory agency) (ACC 2015).
The IDDR includes data on ATS that covers a range of drugs from amphetamine, methylamphetamine and 
phenethylamine (a class of drug that includes MDMA, ‘ecstasy’).
IDRS/EDRS
Both the IDRS and EDRS consist of structured interviews of specific populations of illicit drug users, that is, 
people who inject drugs in the IDRS, and people who use ecstasy (MDMA) and other psychostimulants in 
the EDRS. While these groups have limitations in their generalisability to the Australian population, both data 
sources apply two tests to determine the validity of the responses provided by the users: firstly, key experts in 
the illicit drug field are interviewed, and secondly, analyses of indicator data sources related to illicit drug use  
are performed (NDARC 2015b, NDARC 2015a).
The IDRS and EDRS collect data on several factors, including use, availability, price and purity of 
methylamphetamine and distinguish between its forms—powder (‘speed’), base, crystal (‘ice’ or ‘crystal’)  
and liquid.
ASSAD Survey
The ASSAD survey is a national survey of secondary school students aged between 12 and 17 years which asks 
about their use of tobacco, alcohol and illegal and legal (for non-medical purposes) drugs and their attitudes 
toward these substances. The survey has been conducted every 3 years since 1984. The most recent published 
survey in 2011 included around 25,000 students in years 7 to 12. The information completed in the survey is  
self-reported and therefore should be treated with caution (White & Bariola 2013).
In the ASSAD survey amphetamines include: amphetamines or speed, uppers, MDA, goey, dex, Dexie’s, 
dexamphetamine, ox blood, methylamphetamine or ice, other than for medical reasons.
DUMA
DUMA collects data from police detainees who have been arrested in the previous 48 hours and are being 
held in custody. Interviews are conducted with detainees by trained local staff—interviewers cannot be 
police officers. Participation is voluntary and confidential. Urine specimens are also taken and tested by an 
independent laboratory. More than 80% of individuals agree to the interview and more than 70% agree to give 
urine specimens. 
Data are collected across 9 sites in 6 jurisdictions. Several factors affect the randomness of the sample: detainees 
that are considered to be a risk to the interviewer are excluded; mechanisms such as diversion programs, 
notices to attend court (or equivalent) reduce the number of people brought into the station for processing; 
and as interviews are anonymous, there is no way to track individuals over time (AIC 2015).
In DUMA, amphetamines are classified as methylamphetamine, MDMA, or other amphetamines (including 
prescription amphetamines).
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Glossary
amphetamine: a synthetic stimulant drug that affects the central nervous system and speeds up the messages 
going from the brain to the body. Amphetamines as used in this report also refers to the broad category of 
amphetamines in the ASCDC, which includes both amphetamine and methylamphetamine (ABS 2011).
amphetamine-type stimulants: covers a range of drugs from amphetamine, methylamphetamine 
(methamphetamine) and phenethylamine (a class of drug that includes MDMA, ‘ecstasy’).
arrest: incorporates recorded law enforcement action against a person for suspected unlawful involvement 
in illicit drugs. It incorporates enforcement action by way of arrest, summons, diversion program, cannabis 
expiation notice (South Australia), cannabis intervention requirement (Western Australia), simple cannabis 
offence notice (Australian Capital Territory), drug infringement notice (Northern Territory), and notice to appear 
(Queensland). Some charges may have been subsequently dropped or the defendant may have been  
found guilty.
base: sticky paste form of methylamphetamine.
crystal: crystalline form of methylamphetamine, commonly referred to as ‘ice’.
cap: small amount, typically enough for one injection (see ‘point’ below).
closed treatment episode: a period of contact between a client and a treatment provider or team of 
providers. Each treatment episode has 1 principal drug of concern and 1 main treatment type. If the principal 
drug or main treatment changes, then a new episode is recorded. An episode is closed when treatment is 
completed, there has been no further contact between the client and the treatment provider for 3 months or 
treatment is ceased (see reason for cessation).
consumer: offenders are classified as consumers or providers in order to differentiate between people who 
have been apprehended for trading in, as opposed to using, illicit drugs. Those charged with user-type offences 
(possessing or administering drugs for their own use) are classified as consumers.
detection: in the context of the border environment, the term ‘detection’ refers to the identification of illicit 
drugs by the Australian Customs and Border Protection Service (ACBPS).
frequent users: used weekly or more often.
lifetime use: used at least once in lifetime.
liquid: a liquid form of methylamphetamine, believed to be made by dissolving the powder form 
of methylamphetamine in water. It is generally described by users to be the most potent form of 
methylamphetamine.
meth/amphetamine: an abbreviated term inclusive of both amphetamine and methylamphetamine.
methylamphetamine: a synthetic stimulant drug related to amphetamine.
new users: they were ‘new users’ of the drug since the last data collection period.
phenethylamine: includes, 3,4-methylenedioxymethamphetamine (MDMA), 
3,4-methylenedioxyethylamphetamine (MDEA), 3,4,-methylenedioxyamphetamine (MDA), 
dimethoxyamphetamine (MDA) and paramethoxyamphetamine (PMA).
point: 0.1 gram, although may also be used as a term referring to an amount for one injection (similar to a ‘cap’, 
see above).
powder: powder form of methylamphetamine, commonly referred to as ‘speed’.
purity: the amount of the illegal substance contained in a drug sample, determined by quantitative analysis.
recent use: use in the previous 12 months.
seizure: is the confiscation by a law enforcement agency of a quantity of an illicit drug or regulated drug being 
used or possessed unlawfully, whether or not an arrest is made in conjunction with that confiscation.
significant: refers to a statistically significant increase or decrease between results reported across different 
NDSHS surveys, for example between the 2010 and 2013 surveys (relevant to the Use section only).
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Trends in  
methylamphetamine  
availability,  
use and treatment 
2003–04 to 2013–14
There have been several corresponding trends in the availability,  
use and treatment of methylamphetamines since 2003–04. 
Following a decline between 2006–07 and 2009–10, 
there have been increases across many factors relating to 
methylamphetamines to 2013–14. Arrests, seizures and 
detections have all increased. Users are now favouring the crystal 
form of methylamphetamine. They are using it more frequently, 
and, there appear to be more new users of crystal. There are more 
people in treatment reporting smoking as their usual method  
of use for amphetamines than previously.
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